ANAB – anaptysbio, inc. (US:NASDAQ)
Stock Stats
News
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
AnaptysBio: Upside Constrained By Undifferentiated Data, Legal Uncertainties [Seeking Alpha]
Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings [Yahoo! Finance]
AnaptysBio (ANAB) had its price target raised by Piper Sandler from $67.00 to $95.00. They now have an "overweight" rating on the stock.
AnaptysBio (ANAB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $66.00 price target on the stock.
Form 8-K ANAPTYSBIO, INC For: Apr 20
Form 3 ANAPTYSBIO, INC For: Mar 26 Filed by: GRAY SUSANNAH
Form 4 ANAPTYSBIO, INC For: Mar 30 Filed by: Schmid John P.
Form 144 ANAPTYSBIO, INC Filed by: Schmid John P.
Form 4 ANAPTYSBIO, INC For: Mar 25 Filed by: Faga Daniel
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.